Not currently recruiting at UCSF
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
a study on Hepatitis Delta Virus
Hepatitis Delta Virus Hepatitis Hepatitis D Interferons Interferon alpha-2 Ritonavir Interferon-alpha Peginterferon alfa-2a Lonafarnib PEG IFN-alfa-2a
Lead Scientist at UCSF
- Marina Roytman, Dr.
Marina Roytman, M.D., FACP, is board certified in Internal Medicine and fellowship trained in Medical Education. Her interests include viral hepatitis, drug induced liver injury, autoimmune hepatitis, and medical education. She has won multiple awards for her presentations on hepatitis and drug induced liver injury.
- accepting new patients
- Start Date
- Completion Date
- Eiger BioPharmaceuticals
- Phase 3
- Study Type
- Last Updated